Innovent Biologics Inc (HKEX: 01801), a China-based biopharmaceutical company, announced on Sunday that it has dosed its first patient with diabetic macular edema (DME) in the phase one study of IBI324, a potential first-in-class ophthalmic recombinant human anti-VEGF-A and anti-Ang-2 bispecific antibody.
This Phase 1 dose escalations study (CTR20221524) intends to assess the safety and tolerability of intravitreal injection of IBI324 in patients with DME.
IBI324 is a dual-target specific recombinant fully humanised anti-VEGF-A and anti-Ang-2 bispecific antibody developed by the company, which can achieve anti-angiogenesis, vascular stabilisation and inflammation inhibition by blocking both VEGF-A and Ang-2, aiming to provide more potential clinical benefits to DME patients, such as prolonging the dosing interval and improving treatment compliance.
GSK releases decade-long data on Shingrix efficacy
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients